175 related articles for article (PubMed ID: 3107988)
1. Class 1B agents lidocaine, mexiletine, tocainide, phenytoin.
Rizzon P; Di Biase M; Favale S; Visani L
Eur Heart J; 1987 Mar; 8 Suppl A():21-5. PubMed ID: 3107988
[No Abstract] [Full Text] [Related]
2. Mexiletine and tocainide: a profile of two lidocaine analogs.
Woosley RL
Ration Drug Ther; 1987 Mar; 21(3):1-7. PubMed ID: 3116601
[No Abstract] [Full Text] [Related]
3. Tocainide and mexiletine. Orally effective lidocaine analogues.
Roden DM
Arch Intern Med; 1985 Mar; 145(3):417-8. PubMed ID: 3919665
[No Abstract] [Full Text] [Related]
4. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine.
Snyder DW
J La State Med Soc; 1989 May; 141(5):21-5. PubMed ID: 2499645
[TBL] [Abstract][Full Text] [Related]
5. Tocainide--an alternative to mexiletine.
Drug Ther Bull; 1982 Jul; 20(14):55-6. PubMed ID: 6814882
[No Abstract] [Full Text] [Related]
6. Antiarrhythmic drug therapy of ventricular arrhythmias.
Huang SK; Marcus FI
Curr Probl Cardiol; 1986 Apr; 11(4):177-240. PubMed ID: 3086035
[No Abstract] [Full Text] [Related]
7. Advances in antiarrhythmic therapy. The role of newer antiarrhythmic drugs.
Nademanee K; Singh BN
JAMA; 1982 Jan; 247(2):217-22. PubMed ID: 6796709
[No Abstract] [Full Text] [Related]
8. Efficacy of class Ib (lidocaine-like) antiarrhythmic agents for prevention of sustained ventricular tachycardia secondary to coronary artery disease.
Reiter MJ; Easley AR; Mann DE
Am J Cardiol; 1987 Jun; 59(15):1319-24. PubMed ID: 3109228
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of antiarrhythmic drugs: a review and overview, part II.
Singh BN; Cho YW; Kuemmerle HP
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):185-99. PubMed ID: 6788721
[No Abstract] [Full Text] [Related]
10. Mexiletine and tocainide: does response to one predict response to the other?
Hession M; Blum R; Podrid PJ; Lampert S; Stein J; Lown B
J Am Coll Cardiol; 1986 Feb; 7(2):338-43. PubMed ID: 3080508
[TBL] [Abstract][Full Text] [Related]
11. The role of antiarrhythmic drugs in prevention of sudden cardiac death.
Podrid PJ
Cardiovasc Clin; 1985; 15(3):265-86. PubMed ID: 2421903
[No Abstract] [Full Text] [Related]
12. Therapy with investigational antiarrhythmic drugs.
Mead RH; Harrison DC
Med Clin North Am; 1984 Sep; 68(5):1321-37. PubMed ID: 6436596
[TBL] [Abstract][Full Text] [Related]
13. Ventricular arrhythmias. An assessment of newer therapeutic agents.
Skluth H; Grauer K; Gums J
Postgrad Med; 1989 May; 85(6):137-8, 141-8, 153. PubMed ID: 2496401
[No Abstract] [Full Text] [Related]
14. [Clinical pharmacology of anti-arrhythymia agents. II. Lignocaine, mexiletine, tocainide, phenytoin].
Witkowska M
Kardiol Pol; 1981; 24(11-12):803-13. PubMed ID: 6804681
[No Abstract] [Full Text] [Related]
15. Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing.
Murray KT; Barbey JT; Kopelman HA; Siddoway LA; Echt DS; Woosley RL; Roden DM
Clin Pharmacol Ther; 1989 May; 45(5):553-61. PubMed ID: 2498025
[TBL] [Abstract][Full Text] [Related]
16. [Combination of sotalol with the class I B substances mexiletine or tocainide in complex ventricular extrasystole].
Wagner WL; Manz M; Lüderitz B
Z Kardiol; 1987 May; 76(5):296-302. PubMed ID: 2441535
[TBL] [Abstract][Full Text] [Related]
17. [Drug therapy of arrhythmia in coronary cardiopathy].
Lüderitz B
Clin Ter; 1983 Apr; 105(1):3-11. PubMed ID: 6189663
[No Abstract] [Full Text] [Related]
18. Mexiletine and tocainide: orally active congeners of lidocaine.
Wulf BG
Clin Pharm; 1983; 2(4):340-6. PubMed ID: 6411416
[No Abstract] [Full Text] [Related]
19. New drugs in the management of ventricular arrhythmias.
Sanna GP
G Ital Cardiol; 1984 Oct; 14(10):788-97. PubMed ID: 6083894
[TBL] [Abstract][Full Text] [Related]
20. [Anti-arrhythmia agents (II): Mexiletine, aprindine, tocainide and amiodarone].
Kobayashi K; Itoh S; Fukuzaki H
Nihon Rinsho; 1985 Nov; 43(11):2428-34. PubMed ID: 3936949
[No Abstract] [Full Text] [Related]
[Next] [New Search]
